MABXIENCE FROM LAB TO LIFE
LIVE

Serial Number

79414584

Owner

MABXIENCE RESEARCH, S.L.

Attorney

Arturo Perez-Guerrero

Filing Date

Dec 17, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MABXIENCE FROM LAB TO LIFE Trademark

Serial Number: 79414584 • Registration: 8200228

MABXIENCE FROM LAB TO LIFE is a trademark filed by MABXIENCE RESEARCH, S.L. on December 17, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

MABXIENCE RESEARCH, S.L. (16 trademarks)

C/ Manuel Pombo Angulo, 28 3ª. Planta

Entity Type: 99

Trademark Details

Filing Date

December 17, 2024

Registration Date

April 7, 2026

Published for Opposition

February 17, 2026

Goods & Services

Pharmaceutical preparations for the treatment of ophthalmic diseases and disorders, dermatological diseases and disorders, pharmaceutical preparations for use in treating digestive diseases and disorders, gynecological diseases and disorders, hormonal diseases and disorders, blood disorders, cancer, cardiovascular diseases, vascular diseases, gastrointestinal diseases, genitourinary diseases, genitourinary disorders, immunologic diseases, infectious diseases, inflammatory diseases, metabolic diseases and disorders, neurological diseases, psychiatric diseases, central nervous system; pharmaceutical preparations for the treatment of diseases of the musculoskeletal system, diseases of the respiratory system, circulatory system, circulatory diseases, viral diseases, glaucoma, dental and oral diseases, headaches, migraine, obesity, hepatic treatments, treatment of the liver, cholesterol, blood pressure and rheumatic treatments; veterinary preparations for treating digestive diseases and disorders, gynecological diseases and disorders, blood disorders, cancer, cardiovascular diseases, vascular diseases, gastrointestinal diseases, genitourinary diseases, immunologic diseases, infectious diseases, inflammatory diseases, metabolic diseases and disorders, neurological diseases, central nervous system, musculoskeletal system, respiratory system, circulatory system, viral diseases, glaucoma, dental and oral diseases, headaches, migraine, obesity, hepatic treatments, cholesterol, blood pressure and rheumatic treatments, and dietetic foods adapted for medical use, namely, breads, pastas, crackers, chips, packaged meals, nutritional food bars, candy, dips, sauces and food supplements in pill, powder capsule, beverage form, effervescent tablet and liquid form.

Chemical, biological and pharmaceutical research services.

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 7, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 2, 2026 OPNX
NEW REPRESENTATIVE AT IB RECEIVED
Jun 25, 2026 NREP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 8, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 8, 2026 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 7, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 7, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 17, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 17, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 11, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 23, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 23, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 23, 2026 TROA
REFUSAL PROCESSED BY IB
Aug 22, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 27, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jul 27, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 5, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jun 4, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 3, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 23, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 23, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 23, 2025 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Jan 9, 2025 SDRC